The reliable detection of moderate differences in major health outcomes that arise as a result of treatment requires large-scale randomized evidence (and the appropriate interpretation of this evidence once it has been generated). This may take the form of a single mega-trial or, exceptionally, a meta-analysis of many smaller randomized trials may provide worthwhile information. Small or non-randomized studies cannot generally be trusted to distinguish reliably between a moderate benefit, a moderate hazard, and a negligible difference in major outcomes. Simple design, streamlined data collection, and use of the 'uncertainty principle' to guide eligibility would all encourage the recruitment of larger samples in randomized trials. Future trials need to adopt these methods in order to detect any moderate improvements in major outcomes that may await discovery.
Keywords: randomized controlled trial, meta-analysis large-scale randomized evidence is available (either in one The need to assess MODERATE differences in or two mega-trials or in a large meta-analysis of many outcome smaller trials) moderate distortions can easily be introduced by inappropriate analysis of it, especially if this involves If a widely practicable treatment can achieve just a moderate reduction in a common cause of premature death or of unduly data-dependent emphasis on particular parts of the evidence-for example, on particular trials or on particular serious disability, reliable recognition of this could prevent much suffering. Consider, for example, the case of aspirin, subgroups of patients. which is cheap, practicable, and widely available, and provides just a moderate degree of protection against the How large a reduction in the risk of a major outcome recurrence of myocardial infarction or occlusive stroke [1] .
would be plausible? Worldwide, there are almost 10 million deaths a year from myocardial infarction or stroke [2] , plus a comparable Enthusiasm for the theoretical and experimental foundations of a particular therapeutic approach often leads to exaggerated number of non-fatal (but often seriously disabling ) episodes, and appropriately widespread use of aspirin for the secondary hopes for the effectiveness of that treatment in terms of its effect on major outcomes. These hopes may stem from prevention of vascular disease could well avoid about 100 000 premature deaths annually. dramatic effects on laboratory measures of efficacy, or on the types of surrogate outcomes that are commonly studied Conversely, if a widely used treatment has no material effect on fatal or seriously disabling outcomes (or if an easy, before drugs commence Phase III studies: an anti-cancer drug, for example, may shrink tumours impressively, or a inexpensive treatment is about as good as a more complex one) then reliable demonstration of this could avoid a lot of novel antithrombotic may practically abolish experimental thrombosis. But only rarely do these large effects on trouble, toxicity and expense in future medical practice. Thus clinical research into major outcomes needs to be able surrogate endpoints translate into large effects on major clinical outcomes, and the overwhelming majority of recent to distinguish reliably between a moderate benefit, a moderate hazard and a negligible difference in such improvements in outcome in the common cancers or in the major cardiovascular diseases have generally been only outcomes. By contrast, large differences are so rarely encountered that clinical research strategies should generally moderate in size. Relative risk reductions of only about 10 or 20% are therefore the most that should generally be not be centred on the search for them.
The need to be able to recognise moderate differences in anticipated (which might typically generate absolute differences in a major outcome of a few per cent at most), the chiefly dichotomous outcomes that are of most relevance to patients (e.g. dead/alive; disabled/not) leads, in many whereas relative risk reductions of 50% in the main outcome of interest* are implausible. Future studies aiming to assess cases, to the need for large-scale randomized evidence (and for appropriate analysis of it once it has been generated). The reasons are simple [3] [4] [5] the effects of treatments on major outcomes ought, therefore, subgroups of patients. Although this is often defended as a strategy for understanding trial results in terms of disease to start with the premise that any risk reductions are unlikely to be large. mechanisms, it may lead to seriously misleading results. This is because reliable identification of categories of patient for whom treatment is particularly effective (or ineffective) Two fundamental requirements for the reliable requires surprisingly large quantities of data. Even if the real assessment of moderate treatment effects sizes of the effects of treatment do vary substantially among subgroups of patients, subgroup analyses are so statistically Any study whose main objective is to identify moderate treatment effects must ensure that any biases and random insensitive that they may well fail to demonstrate these differences. On the other hand, even when highly significant errors that are inherent in its design are substantially smaller than the effect which is to be measured. This limits the 'interactions' are found, they may be a poor guide to genuine differences among particular categories of patientsrange of study designs that can be informative (Table 1 ) [6] .
especially when such interactions have emerged after an overzealous examination of multiple subgroups. This might Negligible biases not matter but for the fact that such subgroup analyses are both widely reported and widely believed, which may lead If moderate differences are to be assessed then moderate biases must be avoided, and this often requires appropriate to the inappropriate management of many thousands of patients worldwide. For example, in the large Italian trial, analysis of properly randomized evidence. Non-randomized study designs, in particular, cannot generally be guaranteed GISSI-1, comparing streptokinase vs control after acute myocardial infarction, streptokinase appeared to be beneficial to exclude moderate biases, and are therefore practically useless for the identification of moderate treatment effects.
only among patients without prior myocardial infarction (MI). Fortunately, however, the authors were circumspect Even when studies are properly randomized (and, wherever possible, treatment allocation is concealed) moderate about this finding [7] . This turned out to have been wise since a subsequent overview of all the large fibrinolytic trials biases may be introduced during their analysis or interpretation. This can occur when patients are excluded after showed that the benefits of fibrinolytic therapy after acute MI were similar irrespective of a history of myocardial randomization, particularly when the prognosis of the excluded patients in one treatment group differs from that infarction [8] . Many thousands of patients with a previous history of myocardial infarction might well have been denied in the other (such as might occur, for example, if noncompliers were excluded after randomization). If there is, in fibrinolytic therapy, however, if this observed pattern in the GISSI-1 subgroups had been believed. In general it is reality, virtually no difference in outcome between two treatments, then the least biased assessment of treatment preferable to emphasise the overall results of trials and to regard the results of post-hoc subgroup analyses with healthy effect is that which compares all those allocated to one treatment vs all those allocated to the other (i.e. an scepticism. This example also reinforces the importance, when 'intention-to-treat' analysis), irrespective of what treatment they actually received. Thus, whether analysing just one evaluating the effects of a given treatment on major outcomes, of considering all the randomized evidence, trial or a meta-analysis of many smaller trials, it is important to avoid post-randomization withdrawals.
preferably within a meta-analysis. Such meta-analyses help to avoid unduly data-dependent emphasis on especially A more important bias is that generated by unduly datadependent emphasis on particular trials or on particular striking results within particular trials, and hence provide a better guide to the true effects of treatments. Occasionally, however, when detailed information on individual patients Table 1 Requirements for reliable assessment of MODERATE is available within a meta-analysis that includes several treatment effects [6] .
thousand major outcomes (such as death [8] or recurrence of a major cancer [9] ), it may then be feasible to identify 
hence, they can only ever be small. Either way, complexity is rarely a virtue in trials designed to assess major outcomes, diseases, the results of randomized trials may determine the management of many thousands (and perhaps even millions) whereas simplicity can lead to the randomization of very large numbers of patients and to results which may lead to of future patients. There is an obvious need, therefore, to ensure that they are reliable.
worldwide changes in practice within very short periods of time [1, 8, 11 ]. In general, the scale of randomized evidence that is necessary for the assessment of major outcomes is often not available even through a meta-analysis of all of the completed The 'uncertainty principle': ethicality, heterogeneity randomized trials, since too few major outcomes may have and maximal sample size occurred-even in aggregate-for the results to be trustFor ethical reasons, randomization can be contemplated only worthy. Instead, those who are planning to address the need if both doctor and patient feel substantially uncertain as to for randomized evidence may have to design new ranwhich trial treatment is best. The 'uncertainty principle' domized trials from scratch which, ideally, should aim to maximises the potential for recruitment within this ethical randomize sufficient numbers to generate reliable answers.
constraint. Simply stated, the 'uncertainty principle' is that: Randomized trials have become larger in recent years but still the very largest trials in most specialities do not exceed Patients can be entered only if the responsible physician is a few thousand patients. Even though such trials may seem substantially uncertain as to which of the trial treatments 'large' to those who do the hard work, they may well not would be most appropriate for this particular patient. No be large enough. Consider, for example, a widely practicable patient should be entered if the responsible physician and/or treatment among patients with acute MI that reduces the patient are for any medical or non-medical reason(s) in-hospital mortality from 10% to 8%. If just one million reasonably certain that one of the treatments that might be out of the five million such patients a year were to be allocated would be inappropriate (in comparison with some treated, this would prevent about 20 000 deaths a year, other treatment that could be offered to the patient in the which is a substantial achievement. But, such benefits would trial or outside it) [12] . be surprisingly easy to miss. If, for example, just 2000
This approach to randomization encourages heterogeneity patients were to be randomized, 1000 to active treatment in the resulting trial population and this, in large trials, may and 1000 to control, then we would expect about 80 deaths add substantially to the practical value of the results. Among in the former and 100 in the latter, but even if exactly this the early trials of fibrinolytic therapy, for example, most of result were to be seen it would not be conventionally the studies had restrictive trial entry criteria which presignificant (2P >0.1)-and, by chance alone, the results cluded the randomization of elderly patients, so that these from such a trial might well be about 90 vs 90 deaths instead trials contributed nothing towards answering the important of about 80 vs 100, misleadingly suggesting the treatment to clinical question of whether treatment was useful among be completely useless. Even after randomizing 2000 patients, older patients. Other trials that did not impose an upper age therefore, the real effects of this particular treatment might limit, however, did include some elderly patients, and were remain unclear [6] . What is needed, instead, is to randomize therefore able to show that age alone is not a contraindication 20 000: this would allow the clear demonstration of a 20% to fibrinolytic therapy [8] . reduction with 800 treated and 1000 control deaths
The 'uncertainty principle' ensures not only ethicality and (2P<0.0001), and somewhat smaller benefits which might clinically useful heterogeneity but is also a simple and still be worthwhile could also be detected. practical scheme which encourages the randomization of large numbers of patients. There is scope, therefore, for Randomized trials can be large if they are kept simple many more trials to adopt this as the fundamental principle that determines who is eligible. If trials aiming to assess the effects of treatments on major outcomes are to become substantially larger then as many as Can alternative study designs substitute for large-scale possible of the main barriers to rapid recruitment need to randomized evidence? be removed. One of the most effective ways to guarantee the recruitment of small numbers of patients is to burden
As the resources will never be available to design large, busy clinicians with obtaining large amounts of baseline simple trials to address all the questions of clinical interest, information. The information recorded at entry can often it is reasonable to ask whether there are any circumstances be surprisingly brief, and should concentrate on those few when it might be possible to circumvent the need for large clinical details which are of paramount importance (including trials, either by using routinely collected observational data major prognostic factors and those few variables that are (sometimes referred to as 'Outcomes research') or perhaps thought likely to influence the effect of treatment). Likewise, by analysing previously published randomized trials (within complicated eligibility criteria, inappropriately complex meta-analyses). consent procedures and extensive auditing of data all deter doctors from entering patients into studies. So, by limiting
Outcomes research recruitment, they may result in trials that are too small to identify any moderate effects of treatments on major 'Outcomes research' means various things to various people but, as commonly used, the term refers to the use of outcomes that may truly exist [6] . Furthermore, as well as routinely collected non-randomized data to compare the published (and, hence, are conveniently available) is often a non-random sample of the unconfounded studies, since trials effects of various treatments. Leaving aside the question of whether such research helps in understanding the context of may well be more likely to be submitted for publication if their results are strikingly positive than they are if they are a clinical problem, it cannot avoid moderate biases, and so is of little value for the detection or refutation of moderate negative or null [17] [18] [19] [20] . Such 'publication bias' can, along with other sources of bias, produce surprisingly convincing treatment effects [6, 13] . Even within a carefully designed observational study, where specific arrangements to minimise evidence of effectiveness for treatments that are actually useless [21] . The particular circumstances in which publisources of bias and confounding are planned and monitored, the interpretation of results that correspond to between a cation bias has contributed to producing misleading estimates of treatment are difficult to identify, and it is still more 20% increase or decrease in risk may not be feasible. Uncontrolled, and often uncontrollable, biases or condifficult to generalize about the likely size of such bias when it does occur. But the problem is likely to be particularly founding may be of a similar magnitude to the sort of moderate effect that is to be assessed. It follows, therefore, acute within small meta-analyses that contain less than a few hundred or so major outcomes, and consist chiefly of small that routinely collected data from 'outcomes research' projects are even less likely to be able to detect any moderate trials. This is because the smallest trials are subject to the largest random errors, and are therefore capable of generating effects on outcome, and hence should not be considered as credible evidence if they are so used. This is particularly implausibly large effect estimates. If publication bias results in selected emphasis on some of the most promising of these important when non-randomized studies suggest that particular treatments have surprisingly large effects, since such trials, then the resulting summary odds ratios might well be particularly unreliable [22] . Hence, unless the particular findings are often refuted when those treatments are assessed in large randomized trials [14] .
circumstances of a small-scale meta-analysis suggest that publication bias is unlikely, it may be best to treat the results as no more than 'hypothesis-generating'. On the other hand, Biases and random errors in small-scale meta-analyses a meta-analysis that in aggregate contains sufficient numbers of major outcomes to constitute 'large-scale' randomized Since meta-analyses are appearing in medical journals with increasing frequency it is important that those responsible evidence [1, 8, 9 ] is unlikely to be materially affected by publication bias and, provided there are no serious unconfor the delivery of health care and the planning of future research are able to judge the reliability of such reviews. As trolled biases (see above) within individual component trials, is likely to be trustworthy. for any epidemiological study, the three main sources of mistaken conclusions in meta-analyses are confounding, biases and random errors. In the context of a meta-analysis Conclusions of properly randomized trials, confounding can arise when a 'pure' comparison of treatment A vs control, which aims
The majority of medical interventions that have been subjected to systematic study in large-scale randomized trials to assess the effects of treatment A on a particular outcome, is 'confounded' by the routine co-administration with A of have demonstrated at most only moderate effects on major outcomes such as death or serious disability. But just a a second treatment (B, say) which might be expected to affect the incidence of the same outcome. This problem is moderate effect of treatment, if it can be demonstrated clearly enough for that treatment to be adopted widely, may easily avoided, however, by confining attention to unconfounded randomized trials where treatment A alone is well prevent substantial absolute numbers of premature deaths. Moreover, if a sustained search for moderately compared against control (or when A plus other treatments is compared against those other treatments alone). The main effective treatments is successful-as it has been in myocardial infarction, for example-then the combination of two or problems that then remain are those of biases and random errors.
three individually modest improvements in outcome may collectively result in substantial health gains. There are two main categories of biases which have the potential to affect the reliability of a meta-analysis: those Unfortunately, there is no reliable alternative to largescale randomized evidence for the identification of moderate that occur within individual trials; and those that relate to the selection of trials. Although more empirical research effects on major outcomes, and for most of the important clinical questions where the existing trials do not provide into the numerous biases that can occur within randomized trials would be valuable, it is clear from existing studies, for such evidence the only medically and financially practical way to obtain it is to plan, design and conduct some large example, that inadequate treatment concealment can result in exaggerated estimates of treatment effect [15] , and that simple trials. If this is to happen then it will be important to encourage large-scale collaboration among disease specialthe inappropriate post-randomization exclusion of particular patients is common [16] . The resulting biases may have ists. This, for example, is already the case among those concerned with the treatment of children with acute unpredictable consequences for particular trials, however, so that generalizations about the impact of such biases are lymphoblastic leukaemia in the UK, enabling over 90% of new cases to be entered into Medical Research Council inappropriate.
A potentially more serious problem, however, results trials [23] . Such collaborations are especially important, of course, among those concerned with the treatment of from selection biases associated with the process of identifying all relevant trials (or, on occasions, with the failure to relatively uncommon diseases. Many disease specialists have already begun the important preliminary collaborative task include all such trials once they have been identified). Unfortunately, the subset of trials that are eventually of assembling the randomized evidence relevant to their specialty within a Cochrane Review Group [24] . As well as 
